Phase 4 Chronic Rhinosinusitis Trial, Recruiting NCT05094570 Sponsor: University of Virginia Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Phase 4 Chronic Rhinosinusitis Trial, Recruiting

NCT05094570
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You have been diagnosed with chronic sinusitis with nasal polyps (including if you also have a condition called AERD, which involves sensitivity to aspirin)
  • A recent swab of your sinuses showed a bacteria called Staphylococcus aureus (staph) at your first visit
  • You have previously had sinus surgery, and your sinus openings are clear enough for doctors to take swabs and tissue samples
  • If you have asthma, it is currently well managed
  • If you have eczema (atopic dermatitis), it is currently well managed
  • You are already using saltwater nasal rinses and have been on a stable dose of steroid nasal spray for more than one month
  • Your doctor is already planning to start you on a medication called dupilumab as part of your normal care
  • You meet the FDA's approved guidelines for using dupilumab for nasal polyps

Who may not be able to join:

  • You have another serious medical condition going on at the same time
  • Your asthma is not well controlled (confirm with trial site)
  • You have used steroid tablets or pills in the last 60 days
  • You have had an urgent care visit, emergency room visit, or hospital stay for asthma in the last 60 days
  • You currently smoke, or you have a significant smoking history of more than 10 pack-years (confirm with trial site)
  • You have used a biologic medication (including for asthma) in the last 3 months
  • Your sinus-related medications or treatment routine have changed in the last month
  • You have had a cold or upper respiratory infection in the last 6 weeks
  • You have taken antibiotics in the last 6 weeks
  • You are currently pregnant or breastfeeding
  • You have had a bad reaction to dupilumab before, or have any other medical reason you cannot take it

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Larry C Borish, MD, University of Virginia

Phone: 4349246874

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
1 September 2022
Est. completion
30 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To demonstrate that dupilumab reduces staphylococcus aureus

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov